TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$122.7 Million

Codex DNA Inc.

Initial Public Offering

Bookrunner, June 2021

Codex DNA Inc.

Codex DNA, Inc. (“Codex DNA” or the “Company”) is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Codex DNA developed their synthetic biology solution to address the significant unmet need in the market for an approach that can automate, integrate, optimize and standardize the process for building synthetic DNA and mRNA.